Boston Scientific CorpBSX
Price$43.23Intrinsic value$62.6045% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $21B+25.4% YoYTTM through 30 Jun 2026
Net Income $3.7B+98.7% YoYTTM through 30 Jun 2026
Free Cash Flow $3.6BTTM through 30 Jun 2026

Margins

Current
Gross Margin69.9%
EBITDA Margin26.5%
Operating Margin19.8%
Net Margin17.5%

Returns

14.7%ROE
8.1%ROA
10.4%ROIC

Balance Sheet Health

Debt / Equity0.44x
Current Ratio1.24x
Net Debt$10.4B
Cash & Equivalents$539M

Quality Metrics

Altman Z-Score2.98
Piotroski F-Score6 / 9
FCF Margin17.3%
Rule of 4019.0
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $20.1B
Diluted EPS$2.47TTM
'19'20'21'22'23'24'25
FY2025: $1.94

Dividend

No dividend

Capital Allocation

Capex Intensity4.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.